- Home
- LCTX vs NGEN Comparison
LCTX vs NGEN Comparison
Compare LCTX & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCTX | NGEN |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 314.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | LCTX | NGEN |
|---|---|---|
| Price | $1.38 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $6.25 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.2M | 166.1K |
| Earning Date | 05-14-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,556,000.00 | N/A |
| Revenue This Year | $109.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.45 | $3.51 |
| 52 Week High | $2.09 | $5.93 |
Technical Indicators
Market Signals| Indicator | LCTX | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 44.16 |
| Support Level | $1.14 | $3.65 |
| Resistance Level | $1.80 | $4.44 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.48 | 34.48 |
Price Performance
Historical ComparisonAbout LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.